Details for Patent: 11,666,573
✉ Email this page to a colleague
Which drugs does patent 11,666,573 protect, and when does it expire?
Patent 11,666,573 protects ERZOFRI and is included in one NDA.
This patent has nine patent family members in eight countries.
Summary for Patent: 11,666,573
| Title: | Dosage regimen of paliperidone palmitate extended-release injectable suspension |
| Abstract: | Provided herein are simplified dosing regimens for administering paliperidone palmitate to a patient in need of treatment of schizophrenia or schizoaffective disorders. |
| Inventor(s): | Youxin Li, Chunjie SHA, FengJuan Zhao, Changbing TU, Kaoxiang Sun, Wanhui Liu, Lifang Sun, Ying MENG |
| Assignee: | Luye Innomind Pharma Shijiazhuang Co Ltd |
| Application Number: | US16/759,287 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Compound; |
Drugs Protected by US Patent 11,666,573
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Luye Innomind Pharma | ERZOFRI | paliperidone palmitate | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 216352-001 | Jul 26, 2024 | RX | Yes | Yes | 11,666,573 | ⤷ Start Trial | DOSING REGIMEN FOR THE TREATMENT OF SCHIZOPHRENIA IN ADULTS BY ADMINISTERING AN INITIAL DOSE OF PALIPERIDONE PALMITATE FOLLOWED BY MONTHLY DOSE(S) | ⤷ Start Trial | ||||
| Luye Innomind Pharma | ERZOFRI | paliperidone palmitate | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 216352-001 | Jul 26, 2024 | RX | Yes | Yes | 11,666,573 | ⤷ Start Trial | DOSING REGIMEN FOR THE TREATMENT OF SCHIZOAFFECTIVE DISORDER IN ADULTS AS MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS BY ADMINISTERING AN INITIAL DOSE OF PALIPERIDONE PALMITATE FOLLOWED BY MONTHLY DOSE(S) | ⤷ Start Trial | ||||
| Luye Innomind Pharma | ERZOFRI | paliperidone palmitate | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 216352-002 | Jul 26, 2024 | RX | Yes | Yes | 11,666,573 | ⤷ Start Trial | DOSING REGIMEN FOR THE TREATMENT OF SCHIZOAFFECTIVE DISORDER IN ADULTS AS MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS BY ADMINISTERING AN INITIAL DOSE OF PALIPERIDONE PALMITATE FOLLOWED BY MONTHLY DOSE(S) | ⤷ Start Trial | ||||
| Luye Innomind Pharma | ERZOFRI | paliperidone palmitate | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 216352-002 | Jul 26, 2024 | RX | Yes | Yes | 11,666,573 | ⤷ Start Trial | DOSING REGIMEN FOR THE TREATMENT OF SCHIZOPHRENIA IN ADULTS BY ADMINISTERING AN INITIAL DOSE OF PALIPERIDONE PALMITATE FOLLOWED BY MONTHLY DOSE(S) | ⤷ Start Trial | ||||
| Luye Innomind Pharma | ERZOFRI | paliperidone palmitate | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 216352-003 | Jul 26, 2024 | RX | Yes | Yes | 11,666,573 | ⤷ Start Trial | DOSING REGIMEN FOR THE TREATMENT OF SCHIZOAFFECTIVE DISORDER IN ADULTS AS MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS BY ADMINISTERING AN INITIAL DOSE OF PALIPERIDONE PALMITATE FOLLOWED BY MONTHLY DOSE(S) | ⤷ Start Trial | ||||
| Luye Innomind Pharma | ERZOFRI | paliperidone palmitate | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 216352-003 | Jul 26, 2024 | RX | Yes | Yes | 11,666,573 | ⤷ Start Trial | DOSING REGIMEN FOR THE TREATMENT OF SCHIZOPHRENIA IN ADULTS BY ADMINISTERING AN INITIAL DOSE OF PALIPERIDONE PALMITATE FOLLOWED BY MONTHLY DOSE(S) | ⤷ Start Trial | ||||
| Luye Innomind Pharma | ERZOFRI | paliperidone palmitate | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 216352-004 | Jul 26, 2024 | RX | Yes | Yes | 11,666,573 | ⤷ Start Trial | DOSING REGIMEN FOR THE TREATMENT OF SCHIZOAFFECTIVE DISORDER IN ADULTS AS MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS BY ADMINISTERING AN INITIAL DOSE OF PALIPERIDONE PALMITATE FOLLOWED BY MONTHLY DOSE(S) | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,666,573
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2018354431 | ⤷ Start Trial | |||
| Canada | 3077224 | ⤷ Start Trial | |||
| European Patent Office | 3700531 | ⤷ Start Trial | |||
| Spain | 3036965 | ⤷ Start Trial | |||
| Japan | 2021501200 | ⤷ Start Trial | |||
| Japan | 7337080 | ⤷ Start Trial | |||
| New Zealand | 763573 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
